Sarah West, MD
Hospice and Palliative Medicine · Newport News, VANPI 1629149083
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Among hospice and palliative medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$380
- Johnson & Johnson$317
- Incyte Corporation$250
- Novartis$225
- AbbVie$170
- Eisai Inc.$153
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,007100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 19 | $380 |
| Johnson & Johnson | 12 | $317 |
| Incyte Corporation | 12 | $250 |
| Novartis | 10 | $225 |
| AbbVie | 8 | $170 |
| Eisai Inc. | 7 | $153 |
| Astellas Pharma US Inc | 5 | $121 |
| Servier Pharmaceuticals LLC | 6 | $118 |
| Sanofi | 5 | $110 |
| AstraZeneca | 4 | $105 |
| EMD Serono, Inc. | 5 | $99 |
| Seagen Inc. | 4 | $85 |
| Sobi, Inc | 4 | $75 |
| Beigene USA, Inc. | 4 | $73 |
| Genentech USA, Inc. | 2 | $60 |
| Exelixis Inc. | 2 | $54 |
| Merck | 3 | $52 |
| Pfizer | 2 | $46 |
| Bayer | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Tersera Therapeutics LLC | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Puma Biotechnology, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 2 | $32 |
| Amgen | 2 | $30 |
| Taiho Oncology, Inc. | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Stryker | 1 | $23 |
| Caris MPI, Inc. | 1 | $22 |
| Novocure Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
How this compares
$3,007 in reported general payments places this provider in the 95th percentile of 45 hospice and palliative medicine providers in Virginia.
See all hospice and palliative medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $6,548 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,458 |
| MovantikNaloxegol Oxalate | 13 | $5,300 |
| Fentanyl | 40 | $4,281 |
| Oxycodone Hcl | 172 | $2,617 |
| Duloxetine Hcl | 91 | $1,802 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $925 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $582 |
| Methadone Hcl | 20 | $507 |
| Olanzapine | 42 | $461 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $444 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $400 |
| Fluticasone Propionate | 14 | $275 |
| Gabapentin | 27 | $236 |
| Ondansetron OdtOndansetron | 13 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $317 | $6,54812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 hospice and palliative medicine providers in Virginia.
Other hospice and palliative medicine in Newport News
- Gregory AloufSalem$13K
- Purvi ShahRichmond$9K
- Jessica HeintzFairfax$2K
- Sea KimAlexandria$2K
- Muhammad SiddiquiManassas$948
- Haley VestCharlottesville$534
- Cara JenningsRichmond$458
- Ying LiNorfolk$240
- Prashanta KoiralaWinchester$235
- Ryen ButlerFredericksburg$230
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.